Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
Clinical Benefit
| Substantial |
The actual benefit of XELODA is substantial. |
Clinical Added Value
| no clinical added value |
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator. |
eNq1mF1v2jAUhu/5FVEudkcClK9uCdXGyobUaoyCNu0GmeQAZsFO/cHHfv0cAipMjroafJk4ec+xz/HjVw7utqvEWQPjmJLQrXoV1wES0RiTeeiOR71y273rlIIlWqOTz1pexavWXCdKEOehm416U0CEez8fHz6D+h+Y2yk5AZ0uIRJn30mBE+8r4otHlGbfOMGa4thZgVjQOHRTKfZvnYALprLobCj7zVMUQeAf3pyOLif10/eBn4n9h6rkwB4QmWtFgRhpRpIxIKKLBMwp2xXke2OkjfkQOJUsggESiwGjaxxDrA0xQwkHoyCzTfwEbJ2AyIJoxf1ltOJG4miJtkN47uuT/qhGu2IrypVytdWq1prtRr1VqzeMQrGTpdJXQU3CjybNeq1da/hAfL4jaI65YWkGlAmUWCoK5t3zvrIUh8Hzq8WPMU8TtPOWPDVdKsSQGgamdr+9iWQzGDHFo0St2T/6RCaJ/8asxwdaWMo4g1GXSiIKoNEbmi5ElxIB2+KKmnFObA+9iIFfT/YPJXrGD+Q0wZEp0RRzJHAxHvaLgXZFFnxCHMbMHgx+YBLTDb8+ZE6Lain7dM9JrWjK4uqkdttuVhsN4z30S3VQwflyLxlNwVf4MazsgSp9MqOX8kQ1pV7q2JLX6sa9yaERSqDA5pQNyaLa8OjKrDW6vU2UD2hFv9yPTLvjuwS2e9o/aqVxHB7rakZdGyhXrfha3vmmDdPJTaXRvr2pv0Or9MPRPoeGVjkXteKUJdMTZiFEyt/7/maz8RaIlzlS6+nNWOEBcKed+TVmr2j7Ukx7Xt7K4Z+boZy0llKf5kfo26poum1fsweXWt7D/wdrrY0hmIQLapET3hqH+/fXR/uL37WW9uCMMPbC7L0pEpgSW6ZJTrWKFx0mqqykxxQfvs1muOBqpbAtAz+/1umUAj+70umU/gJxHv9s
72yVAgSUPpusmQHY
Listen
